Aurora Licensing will attend the Zoomark International, organized by Bologna fiere, is the most important pet industry trade show in Europe in 2019.
Zoomark International, organized by Bologna fiere, is the most important pet industry trade show in Europe in 2019. The last edition, in 2017, saw a 17% increase in the number of exhibitors and a 25% rise in the number of trade visitors.Visit us from 6 to 9 May, Pav. 26, Booth B136
PALACIO M. DE CONGRESOS DE MADRID – SPAIN
Nutraceuticals Europe is the right place for generating business, AURORA LICENSING will be there to meet some potential distributors and introduce new medical devices; please write “contact us” and/or subscribe our newsletter to be updated about our events.
STIPSIGOL® is a medical device acting a laxative osmotic action and regulating the intestine in a natural way. STIPSIGOL® is not absorbed by the intestine neither it ferments, it does not irritate the mucosa and it is eliminated by the feces in a not modified form.Continue Reading
The first Italian example of residence-office, the pharmaceutical company Aurora Licensing celebrated the grand opening of the new headquarter close to Loreto square, Milan, Italy: over two thousand square meters with restaurant space, chapel, gym and bed rooms.Continue Reading
AURORA LICENSING will attend an international meeting buyer organized by FEDERSALUS in Milan, a special occasion to discuss partnerships with international operators from Russia, Germany, Saudi Arabia.Continue Reading
The projects of the two companies have the same continuity with the previous 2018, which has represented by massive investments, thanks to the develop of high quality technological products and a focused plan of hires also.
Once again, the two brands objectives will be research and innovation, as the previous development of a high quality technological new probiotic line, Abiflor baby, Abincol ed Abivisor.
ABI-LINE probiotic, was born by the Aurora Biofarma and Aurora Licensing research, the first probiotic product line acting for organ-competence together with an innovative feature: the “strain- specificity”.
The ABI-line probiotic offers an absolute innovation into the probiotic’s world.
Aurora Biofarma closed the 2018 in the domestic market with the goal of 20 million Euro income and a forecast grow of + 35% comparing with the previous year; a new ambitious target is established, passing the amount of 30 million Euro of income in 2020.
AURORA LICENSING will attend an international meeting buyer organized by FEDERSALUS in Milan, a special occasion to discuss partnerships with international operators from Russia, Germany, France, Poland, Saudi Arabi and United Arab Emirates.Continue Reading